Cantor Fitzgerald Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on BioMarin Pharmaceutical today and set a price target of $85.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brayer covers the Healthcare sector, focusing on stocks such as Vanda, BioMarin Pharmaceutical, and Alnylam Pharma. According to TipRanks, Brayer has an average return of 4.1% and a 41.79% success rate on recommended stocks.
In addition to Cantor Fitzgerald, BioMarin Pharmaceutical also received a Buy from Canaccord Genuity’s Whitney Ijem in a report issued on February 26. However, today, H.C. Wainwright reiterated a Hold rating on BioMarin Pharmaceutical (NASDAQ: BMRN).
Based on BioMarin Pharmaceutical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $874.57 million and a GAAP net loss of $46.57 million. In comparison, last year the company earned a revenue of $747.31 million and had a net profit of $124.94 million
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BMRN in relation to earlier this year. Last month, George Eric Davis, the EVP, CLO of BMRN sold 26,061.00 shares for a total of $1,599,102.96.
Read More on BMRN:
